Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an Infusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~1. Male or female subjects aged 18 years and above, who have severe cancer pain.~2. Subjects who require a strong opioid by subcutaneous infusion to stabilise and manage their cancer pain effectively.~3. Subjects who give written informed consent to participate in the study.~4. Subjects who agree to their primary care physician being informed of their participation in the study.~5. Subjects who consent to processing of their trial data according to the requirements of the UK Data Protection Act 1998.~Exclusion Criteria~1. Subjects who are pregnant, lactating or in the Investigators opinion are at risk of conceiving and are not using adequate contraception measures.~2. Subjects with known hypersensitivity (allergic reaction) to oxycodone, any other opioids or any of the excipients.~3. Subjects who are planned to receive chemotherapy during the study treatment period or are currently receiving continuous i.v. chemotherapy infusion.~4. Subjects with neutropenia, thrombocytopenia or coagulation disorders.~5. Subjects with any contraindications to oxycodone as outlined in the Investigator Brochure or Summary Product Information sheet for oxycodone.~6. Subjects who are currently participating in another clinical research study involving a new chemical entity.~7. Subjects whom the Investigator believes to be medically unfit to receive the study medication, or unsuitable for any other reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).